福建广生堂药业股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、福建广生堂药业股份有限公司（以下简称"公司"）股票自 2025 年 7 月 29 日至 7 月 31 日连续三个交易日收盘价格涨幅偏离值累计超过 30%。根据《深 圳证券交易所交易规则》规定，属于股票交易异常波动的情况。根据中证指数有 限公司最新数据显示，截至 2025 年 7 月 30 日，公司的最新市净率为 46.58；公 司所属中上协行业分类"医药制造业（C27）"的最新市净率为 3.17。公司市净 率与同行业的情况有较大差异。公司股价短期内大幅上涨，但公司基本面未发生 重大变化，可能存在股价大幅上涨后回落的风险，郑重提醒广大投资者注意公司 股票二级市场交易风险，理性决策，谨慎投资。 2、公司最近三年及一期经营业绩连续亏损。公司 2022 年至 2025 年第一季 度归属于上市公司股东的净利润分别为-12,740.39 万元、-34,858.98 万元、 -15,630.44 万元，-2,848.89 万元。敬请广大投资者注意投资风险， ...

广生堂7月31日晚间公告，公司股票自2025年7月29日至7月31日连续三个交易日收盘价格涨幅偏离值累 计超过30%。根据《深圳证券交易所交易规则》规定，属于股票交易异常波动的情况。根据中证指数有 限公司最新数据显示，截至2025年7月30日，公司的最新市净率为46.58；公司所属中上协行业分类"医 药制造业（C27）"的最新市净率为3.17。公司市净率与同行业的情况有较大差异。公司股价短期内大幅 上涨，但公司基本面未发生重大变化，可能存在股价大幅上涨后回落的风险，郑重提醒广大投资者注意 公司股票二级市场交易风险，理性决策，谨慎投资。 ...

Group 1 - The core point of the article highlights the performance of A-share stocks in July, with significant gains observed in specific companies [1] - The top performer, Aowei New Materials, achieved a cumulative increase of 1083.42% in July, ranking first among A-share stocks [1] - Guangsheng Tang ranked second with a cumulative increase of 218.94% during the same period [1]

Core Viewpoint - The assisted reproduction sector has shown a positive performance with a 1.72% increase, ranking third among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Sector Performance - As of July 31, the assisted reproduction concept increased by 1.72%, with 34 stocks rising, including Anke Bio and Gongtong Pharmaceutical, which both hit the 20% limit up [1]. - Notable gainers in the sector included Guangshengtang, Xinghao Pharmaceutical, and Hanyu Pharmaceutical, with increases of 18.04%, 8.03%, and 7.02% respectively [1]. - Conversely, stocks such as Jiabiyou, Changchun High-tech, and Zhejiang Medicine experienced declines of 3.70%, 3.02%, and 2.99% respectively [1]. Group 2: Capital Flow - The assisted reproduction sector saw a net inflow of 0.18 billion yuan, with 30 stocks receiving net inflows from major funds [2]. - Anke Bio led the sector with a net inflow of 4.09 billion yuan, followed by Zhongsheng Pharmaceutical and Hanshang Group with net inflows of 2.04 billion yuan and 1.44 billion yuan respectively [2]. - The top three stocks by net inflow ratio were Hanshang Group at 53.93%, Lideman at 35.62%, and Gongtong Pharmaceutical at 23.90% [3].

Market Performance - The three major A-share indices all recorded gains in July, with the Shanghai Composite Index rising by 3.74% to close at 3573 points, marking a three-month consecutive increase [1] - The Shenzhen Component Index increased by 5.2% to 11009 points, while the ChiNext Index surged by 8.14% to 2328 points [1] Sector Performance - The top five performing sectors over the past 20 trading days were: - Hydropower concept up 27.35% - Tibet sector up 25.85% - Engineering machinery up 19.88% - Medical services up 18.17% - CRO concept up 17.36% [2] - Conversely, the five sectors with the largest declines were: - Insurance down 6.27% - Precious metals down 3.57% - Banking down 3.41% - Guangdong Free Trade Zone down 2.23% - Food processing and manufacturing down 1.36% [2] Individual Stock Performance - The top five individual stocks in terms of gains for July were: - Shangwei New Materials up 1083.42% - N Dingjia up 479.12% - C Hanguo up 290.08% - Shanda Power up 228.04% - Guangsheng Tang up 218.94% [2] - The five stocks with the largest declines were: - *ST Zitian down 68.65% - *ST Suwu down 48.02% - *ST Tianmao down 44.16% - Yuandao Communication down 31.83% - ST Yundong down 31.77% [2]

Core Viewpoint - The article highlights a collective rebound in the technology sector, driven by strong performances from Microsoft and Meta, which have ignited interest in the computing power segment and sustained momentum in innovative pharmaceuticals [2][8]. Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index down by 0.68% and the Shenzhen Component Index down by 0.45%, while the ChiNext Index rose by 0.43% [2]. - The total trading volume in the Shanghai and Shenzhen markets exceeded 1.14 trillion yuan, an increase of 562 billion yuan compared to the previous trading day [3]. Technology Sector Performance - Major technology stocks rebounded, with CPO (Cloud Power Optimization), PCB (Printed Circuit Board), and other computing hardware leading the gains. Concepts related to communication and AI also saw renewed activity [3][9]. - CPO concept stocks experienced significant gains, with companies like Ruijie Networks and Cambridge Technology seeing substantial increases in stock prices, with Cambridge Technology hitting the daily limit [10][13]. Innovative Pharmaceuticals - The innovative pharmaceutical sector remained active, with stocks like Nanxin Pharmaceutical and Qizheng Tibetan Medicine hitting the daily limit, indicating strong investor interest [17]. - A report from CITIC Securities suggests that recent policy signals support the development of innovative drugs and medical devices, indicating potential investment opportunities in the medical device sector [22]. Notable Stock Movements - Industrial Fulian's stock surged over 8%, reaching a historical high with a market capitalization of 704.2 billion yuan, surpassing Changjiang Electric Power [15]. - The article also notes significant gains in weight-loss drug stocks, with companies like Anke Bio and Dezheng Health seeing increases of over 6% [20][21].

消息面上，近日，中共中央办公厅、国务院办公厅印发了《育儿补贴制度实施方案》。多部门有关负责 人7月30日在国新办举行的新闻发布会上介绍，2022年1月1日以后出生的符合条件的婴幼儿都可以领取 育儿补贴。按照工作计划，各地将在8月下旬陆续开放育儿补贴申领，8月31日前各地全面开放育儿补贴 的申领。据悉，中央财政将设立共同财政事权转移支付项目"育儿补贴补助资金"，今年初步安排预算 900亿元左右。 国家卫生健康委副主任郭燕红介绍，育儿补贴是新中国成立以来首次大范围、普惠式、直接性向群众发 放的民生保障现金补贴，是一项惠民利民的重大举措。育儿补贴不分城乡、民族、区域，也不分一孩、 二孩或者三孩，实现三孩生育政策下家庭支持的全面覆盖，确保符合条件的婴幼儿能够平等享受补贴的 待遇。 辅助生殖概念31日盘中走势活跃，截至发稿，共同药业（300966）、利德曼（300289）20%涨停，广生 堂（300436）涨超15%，安科生物（300009）涨近14%，汉商集团（600774）亦涨停。 万联证券指出，短期来看，育儿补贴的发放有助于直接刺激母婴相关的消费，建议关注婴童护理、乳制 品、玩具、童装等行业；长期来看，生育补贴和 ...

A股辅助生殖板块持续走强，福元医药盘中创历史新高，共同药业、汉商集团、利德曼涨停，安科生物 涨超15%，广生堂涨超10%，新光药业、达嘉维康、贝因美、星昊医药、贝瑞基因跟涨。 ...

Core Viewpoint - The assisted reproductive industry has experienced significant growth, with several companies seeing substantial stock price increases, indicating a bullish market sentiment towards this sector [1] Company Performance - Joint Pharmaceutical (300966) and Lide Man (300289) both reached a 20% limit up in stock price [1] - Anke Biotechnology (300009) saw an increase of over 12% in its stock price [1] - Han Commercial Group (600774) also hit the limit up [1] - Dajia Weikang (301126) and Guangshengtang (300436) experienced notable stock price increases as well [1]

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a significant rebound, with numerous stocks doubling in value and a strong performance from innovative drug companies, indicating a potential for continued growth and investment opportunities [1][2][3]. Group 1: Market Performance - As of July 29, 2023, the pharmaceutical sector has seen 42 stocks double in value this year, with Shuyatain leading at a 560% increase [1]. - Eight stocks, including Saifen Technology and Yipin Hong, have risen over 200%, while over 30 stocks have increased by more than 100% [1]. Group 2: Fund Performance - The surge in the pharmaceutical sector has led to significant gains in several pharmaceutical-themed funds, with many achieving over 100% returns in the past year [2]. - Fund managers believe that innovative drugs are likely to gain traction due to high demand and the upcoming product launches from various A-share and H-share companies [2]. Group 3: Industry Insights - Analysts highlight that the innovative drug sector is entering a golden development phase, supported by short-term performance from research outcomes and long-term benefits from aging populations and health demand upgrades [2]. - The innovative drug sector is seen as the most promising sub-industry within pharmaceuticals, with a clear growth trajectory and investment potential [3]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from a combination of policy support and fundamental growth, leading to a revaluation of the sector [3]. - Analysts recommend continued investment in specific segments such as CRO & CDMO, GLP-1, and unique raw materials, which are anticipated to show strong performance [3].